Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_1
2
100%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Other(2)

Detailed Status

unknown2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 12 (100.0%)

Trials by Status

unknown2100%

Recent Activity

0 active trials
Showing 2 of 2
unknownphase_1

HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors

NCT05360381
unknownphase_1

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors

NCT05442996

Clinical Trials (2)

Showing 2 of 2 trials
NCT05360381Phase 1

HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors

Unknown
NCT05442996Phase 1

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors

Unknown

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2